Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Nishioka N, et al. Among authors: ninomiya t. Target Oncol. 2024 May;19(3):423-433. doi: 10.1007/s11523-024-01048-x. Epub 2024 Apr 13. Target Oncol. 2024. PMID: 38613731 Free PMC article.
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K. Isozaki H, et al. Among authors: ninomiya t. Cancer Res. 2016 Mar 15;76(6):1506-16. doi: 10.1158/0008-5472.CAN-15-1010. Epub 2015 Dec 30. Cancer Res. 2016. PMID: 26719536
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T, Yanagitani N, Mizutani H, Ninomiya T, Kajiwara T, Ito K, Miyanaga A, Arai D, Kodama H, Kobayashi K, Kaira K. Nakamura A, et al. Among authors: ninomiya t. Eur J Cancer. 2023 May;184:62-72. doi: 10.1016/j.ejca.2023.01.025. Epub 2023 Feb 11. Eur J Cancer. 2023. PMID: 36905770
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K. Oda N, et al. Among authors: ninomiya t, ninomiya k. Clin Lung Cancer. 2017 Mar;18(2):241-244. doi: 10.1016/j.cllc.2016.07.003. Epub 2016 Jul 9. Clin Lung Cancer. 2017. PMID: 27506489 Clinical Trial.
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K. Kudo K, et al. Among authors: ninomiya t. Mol Oncol. 2017 Jun;11(6):670-681. doi: 10.1002/1878-0261.12063. Epub 2017 May 2. Mol Oncol. 2017. PMID: 28388009 Free PMC article.
Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
Kubo T, Watanabe H, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Rai K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K. Kubo T, et al. Among authors: ninomiya t, ninomiya k. Jpn J Clin Oncol. 2020 Dec 16;50(12):1447-1453. doi: 10.1093/jjco/hyaa152. Jpn J Clin Oncol. 2020. PMID: 32869100
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.
Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Ichihara E, Kuyama S, Kudo K, Bessho A, Sakugawa M, Fujimoto N, Aoe K, Minami D, Sugimoto K, Ochi N, Takigawa N, Hotta K, Maeda Y, Kiura K. Ninomiya T, et al. Jpn J Clin Oncol. 2021 Aug 1;51(8):1269-1276. doi: 10.1093/jjco/hyab084. Jpn J Clin Oncol. 2021. PMID: 34115855 Clinical Trial.
1,155 results